Immuno-Oncology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Immuno-Oncology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Cancer, a relentless global health challenge, is the second-leading cause of death worldwide, following cardiovascular disease. According to the World Health Organization (WHO), an estimated 8.3 million lives are claimed by cancer annually, with approximately 70% of new cancer cases expected to be reported over the next two decades.

Rising Prevalence of Cancer and Personalized Medicine Driving Demand for Immuno-Oncology Treatments

With over 60 percent of new cancer cases occurring in Africa, Asia, Central and South America, and 70 percent of cancer deaths concentrated in these regions, there is a pressing need for effective cancer treatments. Each type of cancer demands unique immuno-oncology therapies. The increasing prevalence of cancer, coupled with the demand for personalized medicine, is anticipated to fuel the global immuno-oncology market.

Technological Advancements Paving the Way for Immuno-Oncology Therapy

Immuno-oncology therapy holds significant promise for cancer treatment. Recent breakthroughs in drug discovery and development highlight its potential in revolutionizing cancer therapy. Advances in clinical trials and FDA approvals of immuno-oncology therapies are fostering the integration of advanced technologies into the field.

Western countries have embraced immuno-oncology therapies due to their well-tolerated adverse event profile compared to conventional chemotherapy. The surge in demand for innovative immuno-oncology therapies is propelling global market growth.

Companion Diagnostics and Predictive Biomarkers Shaping the Future

Biomarkers and pharmacogenomics play a pivotal role in identifying patient responses to immuno-oncology therapy-based treatments. This knowledge maximizes treatment benefits. Companies are actively involved in co-developing companion diagnostics and gaining regulatory approvals for use alongside immuno-oncology therapies, further bolstering market growth.

Manufacturing Challenges Impacting Product Availability

Manufacturers of immuno-oncology therapy-based treatments face complexity in production, limiting the number of organizations capable of providing the solutions sought by drug developers. Contract manufacturing organizations (CMOs) are working to expand their capabilities to manufacture complex immunotherapies. These challenges, along with the high cost of immuno-oncology therapy-based treatments, are expected to impact market growth.

Analysts’ Viewpoint

Our analysts observe that the global immuno-oncology market is experiencing impressive growth, with North America and Europe leading the demand. Developed countries such as the U.S., Mexico, and Germany are witnessing increased acceptance of immuno-oncology therapy-based treatments.

The Asia Pacific region is expected to witness robust growth due to rising cancer prevalence and the preference for immuno-oncology therapies over chemotherapy. Additionally, the demand for biomarker-based immuno-oncology therapy and growing awareness of early cancer detection and treatment are driving market growth.

However, challenges such as high drug pricing, development costs, and limited technical expertise may hinder market growth.

Key Segments of the Immuno-Oncology Market

This report divides the immuno-oncology market into four critical segments: therapy type, therapeutic area, end user, and region. It offers comprehensive insights into the market dynamics and growth factors associated with these categories.

Therapy Type
• Immune Checkpoint Inhibitors
PD-1
PD-L1
CTLA-4
• Immune System Modulators
• Cancer Vaccines
• Oncolytic Virus
• Others (Immune Cell Therapy, etc.)

Therapeutic Area
• Melanoma
• Lung Cancer
• Blood Cancers
• Renal Cell Carcinoma
• Prostate Cancer
• Bladder Cancer
• Other Cancers

End User
• Hospitals
• Clinics
• Ambulatory Surgical Centers

Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.